Search

Author/Creator Fortner, Christopher

2. Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Issue 7 (July 2021)

Authors:
Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Ne...
Journal:
Lancet
Issue:
Volume 9:Issue 7(2021)
Page Start:
733
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Issue 4 (April 2023)

Authors:
Mayer-Hamblett, Nicole; Ratjen, Felix; Russell, Renee; Donaldson, Scott H; Riekert, Kristin A; Sawicki, Gregory S; Odem-Davis, Katherine; Young, Julia K; Rosenbluth, Daniel; Taylor-Cousar, Jennifer L; Goss, Christopher H; Retsch-Bogart, George; Clancy, John Paul; Genatossio, Alan; O'Sullivan, Bri...
Journal:
Lancet
Issue:
Volume 11:Issue 4(2023)
Page Start:
329
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search